Título: Profesor Titular
E-mail: [email protected]
Lattes: http://lattes.cnpq.br/4313449638231391
Orcid: ID 0000-0002-1128-7292 – https://orcid.org/0000-0002-1128-7292
Scopus: ID 56310968200 – https://www.scopus.com/authid/detail.uri?authorId=56310968200
Google scholar: ID 1jhdy0maaaaj – https://scholar.google.com.br/citations?user=1jhdY0MAAAAJ&hl=pt-BR&oi=ao
Research ID: P-8336-2015 – https://publons.com/researcher/2326878/olavo-pires-camargo/

Linha de pesquisa:

Ortopedia Oncológica – Ressecção e reconstrução de tumores ósseos e partes moles.

Resumo

Damos ênfase no diagnóstico e tratamento dos tumores ósseos e de partes moles com reconstrução com endopróteses modulares e com aloenxerto. Também nas ressecções do sarcoma de partes moles de extremidades com reconstrução microcirúrgica. Nas lesões ósseas metastáticas atua na fixação intramedular com haste bloqueada e endoprótese modular.

Artigos relevantes::

  1. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, Figueiredo MT, Marques E, De Bellis N, Consentino E, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer. 1991;68(4):733-7.
  2. Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 1999;18(5):364-8.
  3. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E; Brazilian Osteosarcoma Treatment Group Studies III and IV. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161-8.
  4. Cabrita HB, Croci AT, Camargo OP, Lima AL. Prospective study of the treatment of infected hip arthroplasties with or without the use of an antibiotic-loaded cement spacer. Clinics (Sao Paulo). 2007;62(2):99-108.
  5. Bispo Júnior RZ, Camargo OP. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo). 2009;64(12):1177-86.